NOVARTIS AG
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Large accelerated filer
State of Incorporation Switzerland
Business Address LICHTSTRASSE 35, BASEL, V8, CH 4056
Mailing Address LICHTSTRASSE 35, BASEL, V8, CH 4056
Phone 01141613241111
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | February 4, 2026 | View on SEC |
| 6-K Foreign company current report | February 4, 2026 | View on SEC |
| 6-K Foreign company current report | February 4, 2026 | View on SEC |
| 6-K Foreign company current report | November 25, 2025 | View on SEC |
| 6-K Foreign company current report | November 20, 2025 | View on SEC |
| 6-K Foreign company current report | November 5, 2025 | View on SEC |
| 424B5 Prospectus supplement | November 4, 2025 | View on SEC |
| 424B5 Prospectus supplement | November 3, 2025 | View on SEC |
| 6-K Foreign company current report | October 28, 2025 | View on SEC |
| 3 Initial insider ownership report | October 28, 2025 | View on SEC |
Annual Reports
20-F February 4, 2026
- Novartis completed a major strategic transformation, spinning off Sandoz to focus solely on innovative medicines.
- Achieved strong financial performance in fiscal year 2023, with net sales growing 10% (at constant currencies) to $50.2 billion and core operating income up 18%.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.